Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation
Microbiome in Cancer Patients Undergoing High Dose Chemotherapy With Stem Cell Transplantation
National Cancer Institute, Slovakia
100 participants
Mar 1, 2021
INTERVENTIONAL
Conditions
Summary
Numerous in vitro and animal studies as well as growing number of clinical studies support the important role of microbiome in carcinogenesis and cancer treatment. Detection of changes in patients´ microbiome following hematopoietic cell transplantation/CAR-T cell therapy and correlations with adverse transplant outcomes, mainly infectious complications, acute and chronic GvHD, disease recurrence etc. could serve as predictive markers of immune recovery and treatment response.
Eligibility
Inclusion Criteria3
- signed written informed consent
- aged 18 years or older
- patients planned to be treated by high-dose chemotherapy and hematopoietic cell transplantation or by CAR-T cell therapy in National Cancer Institute, Slovakia
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Sampling of blood and urine for miR and chemokine detection. Sampling of stool for for microbiome studies.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04691284